1038915-90-0

Basic information

• Product Name: methyl 2-{4-[1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylate
• Synonyms: methyl 2-{4-[1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylate
• CAS NO: 1038915-90-0
• Molecular Weight: 435.523
• Mol File: 1038915-90-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: methyl 2-{4-[1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-{4-[1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylate(1038915-90-0)
• EPA Substance Registry System: methyl 2-{4-[1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylate(1038915-90-0)

Safety Data

• Hazardous Substances Data: 1038915-90-0(Hazardous Substances Data)

Usage

General Description

Methyl 2-{4-[1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylate is a chemical compound with the molecular formula C27H29N3O4. It is a derivative of the indazole class of compounds and contains a methyl ester group, a piperidine moiety, and a phenyl group. This chemical has potential applications in pharmaceutical research and drug development due to its structural features, which may make it suitable for use as a building block in the synthesis of bioactive molecules. Additionally, the presence of a piperidine ring in the molecule suggests that it may have pharmacological properties, although further research is needed to explore its potential biological activities.

Upstream product

• 132874-06-7 methyl 3-(bromomethyl)-2-nitrobenzoate 
• 875798-79-1 3-(4-aminophenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 750585-94-5 2-bromo-3-formyl-benzoic acid methyl ester 
• 67-56-1 methanol 
• 1056971-32-4 tert-butyl-3-phenylpiperidine-1-carboxylate 
• 134-20-3 2-carbomethoxyaniline 
• 138229-59-1 3-formyl-2-nitrobenzoic acid methyl ester 
• 5471-82-9 methyl 3-methyl-2-nitrobenzoate 
• 5437-38-7 3-methyl-2-nitrobenzoic acid 
• 1038915-99-9 tert-butyl 3-[4-({[3-(methoxycarbonyl)-2-nitrophenyl]methylene}amino)phenyl]piperidine-1-carboxylate 

Downstream Products

• 1038915-92-2 tert-butyl 3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}-piperidine-1-carboxylate 
• 1038915-60-4 (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine 
• 1038915-58-0 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide 

Relevant articles and documents

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

Synthesis method for preparing PARP inhibitor Niraparib

The invention provides a novel synthesis method for preparing a PARP inhibitor Niraparib. The method comprises the steps that a starting material methyl anthranilate is subjected to diazo coupling, cyclization, amidation, BOC removal and chiral resolution, and then the Niraparib with the purity reaching 99.5% is obtained. The method is simple, convenient and easy to operate suitable for industrial production.

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

We disclose the development of a novel series of 2-phenyl-2H-indazole-7- carboxamides as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.